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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYIn this study, we sought evidence for alpha-synuclein (ASYN) expression in oligodendrocytes, as a possible endogenous source of ASYN
to explain its presence in glial inclusions found in multiple system atrophy (MSA) and Parkinson’s disease (PD). We identified ASYN in
oligodendrocyte lineage progenitors isolated from the rodent brain, in oligodendrocytes generated from embryonic stem cells, and in
induced pluripotent stem cells produced from fibroblasts of a healthy individual and patients diagnosed with MSA or PD, in cultures
in vitro. Notably, we observed a significant decrease in ASYN during oligodendrocyte maturation. Additionally, we show the presence of
transcripts in PDGFRA/CD140a+ cells and SOX10+ oligodendrocyte lineage nuclei isolated by FACS from rodent and human healthy
and diseased brains, respectively. Our work identifies ASYN in oligodendrocyte lineage cells, and it offers additional in vitro cellular
models that should provide significant insights of the functional implication of ASYN during oligodendrocyte development and
disease.INTRODUCTION
Multiple system atrophy (MSA) and Parkinson’s disease
(PD) are adult-onset progressive neurodegenerative dis-
eases that are hallmarked at the cellular level by the
presence of alpha-synuclein (ASYN) protein containing
inclusions. Interestingly, the inclusions are found in
neurons in PD, where the SNCA gene encoding for ASYN
protein is expressed, whereas they are prominent in
oligodendrocytes as glial cytoplasmic inclusions (GCIs)
in MSA (Papp et al., 1989; Stefanova et al., 2009). Because
strong evidence showing that oligodendrocytes in the
adult brain are capable of expressing SNCA is lacking,
recent studies inspired from parkinsonian experimental
models have proposed the interesting hypothesis that
ASYN present in GCIs in MSA could be of neuronal origin
and transfer to oligodendrocytes (Kisos et al., 2012; Reyes
et al., 2014), where it would accumulate and potentially
lead to oligodendrocyte dysfunction. However, more
than a decade ago, Richter-Landsberg and coworkers re-
ported on the transient expression of Snca in cultures
enriched in oligodendrocytes, prepared by mechanical
shaking of mixed rat glial primary brain cultures
(Richter-Landsberg et al., 2000). This finding, however,
was neither confirmed nor further explored, and in vivo
evidences of ASYN expression during oligodendrocyte
maturation are still missing. Consequently, follow-up174 Stem Cell Reports j Vol. 5 j 174–184 j August 11, 2015 j ª2015 The Autstudies mainly focused on understanding the functional
consequences of wild-type or mutant human ASYN tar-
geted expression in oligodendrocytes in experimental
models in vivo and in vitro (Kragh et al., 2013; Yazawa
et al., 2005).
To date, the origin of ASYN in GCIs in oligodendrocytes
in MSA is still elusive, as is that of the few inclusions found
in glial cells in the substantia nigra of people with PD
(Wakabayashi et al., 2000). For these reasons, ASYN expres-
sion in oligodendrocytes remains to be firmly established,
especially since investigations using patient material are
still controversial (Asi et al., 2014; Miller et al., 2005).
One way to explore ASYN expression in human oligoden-
drocytes is through the generation of human cellular
models such as induced pluripotent stem cells (iPSCs),
since patient oligodendrocytes are not always accessible
postmortem.
Here using several murine and human cellular models,
we present compelling evidence for ASYN expression
during oligodendrocyte lineage cell development. More-
over, we identified both ASYN protein and transcripts in
purified PDGFRA/CD140a+ oligodendrocyte progenitors
and oligodendrocyte lineage SOX10+ nuclei, isolated by
fluorescence-activated cell sorting (FACS) from the rodent
wild-type brain and human healthy and diseased brains,
respectively, therefore substantiating a functional role for
ASYN in oligodendrocytes.hors
Figure 1. Localization of ASYN in Mouse
Primary Neurons and Pre-oligodendro-
cyte Progenitors
(A) Experimental approach used for gener-
ating rodent postnatal primary forebrain
cultures is shown.
(B) Rodent postnatal primary forebrain
cultures aged 25 DIV contain B-III-TUB+
neurons expressing Snca. The scale bar
represents 50 mm.
(C) Rodent postnatal primary forebrain
cultures contain O4+ oligodendrocytes ex-
pressing ASYN. Nuclei are counterstained
with DAPI. (Right) Higher magnification of
the region of interest is shown. The scale
bar represents 50 mm.
(D) Quantification of neurons (B-III-TUB+),
oligodendrocytes (O4+), astrocytes (GFAP+),
and microglia (IBA1+ and GAL-3+) co-ex-
pressing ASYN (white bars). Black bars
represent quantification for each cell type.
Values are indicated as the number of cells
per field of view. Mean ± SEM; n = 3 inde-
pendent cultures.
(E) Quantitative real-time PCR analysis
shows the abundance (>10-fold) of Snca
transcripts in FACS-purified O4+ oligoden-
drocyte samples compared to whole primary
culture sample. Oligodendrocyte enrichment
is assessed by the quantification of oligo-
dendrocyte-specific marker transcripts and
the absence of astrocytic Gfap transcripts
(see Supplemental Experimental Proce-
dures). Mean ± SEM; n = 3–4 independent
experiments; t test, *p < 0.05, **p < 0.01.
(F) The set of primers we designed to assess
mouse Snca expression by quantitative real-
time PCR recognizes a unique product of
271 bp and was tested on two independent
cultures.
(G) Quantitative real-time PCR analysis shows significant enrichment in Cyclin-D1 transcripts in purified O4+ oligodendrocyte sample
compared to whole primary culture sample. Mean ± SEM; n = 3 independent experiments; t test, *p < 0.05.
(H) Identification of KI67+/O4+/ASYN+ oligodendrocyte in rodent postnatal primary forebrain culture. Nuclei are counterstained with
DAPI. Insets show higher magnification of the region indicated with straight lines. The scale bar represents 50 mm.RESULTS
ASYN Protein and Transcripts Identified in O4+
Oligodendrocytes in Mouse Brain Primary Cultures
Oligodendrocytes are abundantly produced during devel-
opment and at neonatal age (Kessaris et al., 2006). The
postnatal forebrain, therefore, should provide a rapid
source of oligodendrocytes at different stages ofmaturation
for experimental investigations in vitro.
We performed immunocytochemistry (ICC) on disso-
ciated cell cultures from mouse neonates, grown forStem C3 weeks in vitro (Figure 1A). These cultures were
composed of beta-III-tubulin (B-III-TUB)-expressing neu-
rons (z2%), glial-fibrillary acidic protein (GFAP)-ex-
pressing astrocytes (z75%), IBA1-expressing microglia
(z15%), and oligodendrocyte lineage-specific glycolipid
antigen (O4)-positive oligodendrocytes (z8%) (Figures
1B–1D; Figure S1A). Importantly, ICC for each of
these cell-type-specific markers and ASYN showed spe-
cific localization of ASYN in B-III-TUB+ neurons and
in O4+ oligodendrocytes (Figures 1B–1D; Figures S1A
and S1B).ell Reports j Vol. 5 j 174–184 j August 11, 2015 j ª2015 The Authors 175
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We isolated O4+ oligodendrocytes by FACS from the rest
of thecells present inourprimary cultures, andwemeasured
the abundance of total Snca transcripts by quantitative real-
time PCR. Consistent over multiple rounds of experiments,
our quantitative real-time PCRdata clearly showed the pres-
ence of Snca transcripts (>10-fold increase relative to the
whole culture) in the O4+-purified samples (Figures 1E and
1F), therefore suggesting that O4+ oligodendrocytes indeed
do express the Snca gene encoding for ASYN.
Interestingly, we identified ASYN protein and Snca tran-
scripts in cycling oligodendrocytes, probably oligodendro-
cyte progenitors (Figures 1G and 1H).
Decreased ASYN Expression during Oligodendrocyte
Maturation
To become mature and capable of myelinating axons, oli-
godendrocytes undergo different stages of maturation,
each characterized by temporal expression of specific
markers (Zhang, 2001).
Interestingly, while we previously found that >90% of
O4+ immature oligodendrocytes present in mice primary
postnatal forebrain cultures co-expressed ASYN, we ob-
served a strong reduction (up to 70% less compared to O4+
oligodendrocytes) in co-expressionof ASYNand themature
oligodendrocyte markers 20,30-cyclic nucleotide 30-phos-
phodiesterase (CNPASE, <40%), galactocerebroside (GAL-
C, <35%), and myelin basic protein (MBP, <25%), clearly
identifiable by confocalmicroscopy (Figures 2A and 2B; Fig-
ure S2). In marked contrast, ASYN expression was high in
immature platelet-derived growth factor receptor alpha-
positive (PDGFRA) oligodendrocyte progenitors, measuredFigure 2. ASYN Expression Decreases during Oligodendrocyte Mat
(A) Absence of ASYN in RIP+ and MBP+ oligodendrocytes detected by
bodies. The scale bar represents 50 mm.
(B) Rodent postnatal primary forebrain cultures containO4+ immature olig
GAL-C+, and MBP+ (<20% for all three markers) mature oligodendrocytes.
expression between ASYN and CNPASE, GAL-C, or MBP compared to O4+
(C) Rodent postnatal primary forebrain cultures contain PDGFRA+ oligo
with DAPI. White arrowhead pinpoints an O4/ASYN+/PDGFRA+ oligo
(D) Quantitative real-time PCR analysis shows the abundance (>10-f
progenitor samples compared to PDGFRA+ oligodendrocyte progenito
assessed by the quantification of Pdgfra transcripts and the absenc
Mean ± SEM; n = 2–3 independent experiments.
(E) Experimental approach used for assessing ASYN expression during r
blastocyste aged E3.5 and subsequently differentiated into oligodend
(F) Quantitative real-time PCR shows the loss of Oct4 and upregulati
entiation of mESCs into oligodendrocytes. For each marker, values are
independent experiments.
(G) Western blotting confirms the downregulation of OCT4 and expre
entiation of mESCs into oligodendrocytes. Blot is representative of t
(H) ICC on mESC-differentiated cultures aged 36 DIV confirms the p
oligodendrocytes, respectively. Quantifications are based on two dif
ferentiations. Scale bars represent 50 mm.
Stem Cby ICC and quantitative real-time PCR (Figures 2C and
2D). Our data, therefore, suggest that ASYN expression de-
creases during oligodendrocyte maturation and is present
as early as PDGFRA+ oligodendrocyte progenitor stage.
To ascertain that ASYN expression was specific to oligo-
dendrocyte development and not the result of a transient
expression due to the passage of cells isolated from the
brain to an in vitro culture system, we investigated ASYN
expression during the generation of oligodendrocytes
from mouse embryonic stem cells (mESCs; Figure 2E). We
derived ESC from wild-type mice, which we differentiated
into oligodendrocytes using a previously published proto-
col (Czepiel et al., 2011). We first ascertained the downre-
gulation and upregulation of pluripotent marker Oct4
and oligodendrocyte lineage-specific markers SRY (sex-
determining region Y)-box 10 (SOX10), PDGFRA, CNPASE,
andMBP, respectively, by quantitative real-time PCR, west-
ern blot, and ICC (Figures 2F–2H; data not shown), during
mESC differentiation. We next confirmed the abundance
of Snca transcripts and ASYN protein in our cultures, by
quantitative real-time PCR, western blot, and ICC (Figures
2F–2H). Importantly, we found that the majority of O4+
oligodendrocytes expressed Snca (Figure 2H), and that,
yet again, ASYN decreases during oligodendrocyte matura-
tion (Figure 2H).
Oligodendrocytes Generated from iPSCs from a
Healthy Individual and Patients with PD or MSA Also
Express SNCA
Because ASYN expression in oligodendrocytes from MSA
patients is debated and that in oligodendrocytes of peopleuration
confocal microscopy. White arrows pinpoint oligodendrocyte cell
odendrocytes (z70%of total oligodendrocytemarkers) and CNPASE+,
Mean± SEM; n = 2–3 independent experiments. There is decreased co-
oligodendrocytes. Mean ± SEM; n = 2–3 independent experiments.
dendrocyte progenitors expressing ASYN. Nuclei are counterstained
dendrocyte progenitor. The scale bar represents 50 mm.
old) of Snca transcripts in FACS-purified PDGFRA+ oligodendrocyte
r-depleted samples. Enrichment in oligodendrocyte progenitors is
e of astrocytic Gfap and mature oligodendrocytic Mbp transcripts.
odent oligodendrocyte development. The mESCs were derived from a
rocytes for a period of 4–5 weeks in vitro.
on of Nkx2.2, Pdgfra, Cnpase and Mbp, and Snca during the differ-
presented as a percentage of the highest value. Mean ± SEM; n = 2
ssion of the oligodendroglial markers and ASYN during the differ-
wo independent experiments.
resence and absence of ASYN in PDGFRA+ and CNPASE+, and MBP+
ferentiations. Images are representative of four independent dif-
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with PD is still elusive, we generated iPSCs from fibroblasts
(Figure 3A) of MSA patients diagnosed with cerebellar
ataxia (MSA-C, patient 4) or parkinsonism (MSA-C, pa-
tient 6), a patient diagnosed with a familial form of PD (pa-
tient 3), and a healthy individual (patient 9), and assessed
ASYN expression in oligodendrocyte lineage cells (Fig-
ure 3A). All iPSC clones selected were expanded and cryo-
preserved. Random clones were selected and processed
for further analysis. Thus, clones CSC-3A, B, G, and S;
CSC-4A and B; CSC-6A; and CSC-9A and B underwent
rigorous characterization through a battery of tests (sum-
marized in Figure S3), which indicated that we had effec-
tively generated iPSCs.
We attempted to generate oligodendrocytes from our
iPSC lines. To rule out the possibility of chromosomal ab-
normalities influencing ASYN expression in iPSC-derived
oligodendrocytes, we selected one clone per patient-
specific iPSC line presenting a normal karyotype to carry
out most of our investigations. We devised a protocol,
modified from that of Stacpoole and coworkers (Stacpoole
et al., 2013), where we employed dual inhibition of
SMAD signaling by small molecules LDN and SB to
neutralize our cultures, sonic hedgehog-mediated ventral
patterning, and PDGF-AA/IGF1/NT3/T3/HGF-mediated
terminal differentiation. This modified protocol, proven
efficient when applied to the human ESC lines H13 and
H3 (Figure S4; data not shown), successfully produced
oligodendrocyte progenitor cells (OPCs) and mature oli-
godendrocytes from iPSCs. Thus, by 60 days in vitro
(DIV), nearly all SOX10+ cells co-expressed NKX2.2 and
OLIG2, NG2, and PDGFRA and O4 (Figures S5A–S5C
and S6A), and those cells exhibited in majority an imma-
ture-bipolar morphology where ASYN could clearly be
identified by confocal microscopy, quantitative real-time
PCR, and western blot (Figures 3B and 3C; Figures S5
and S6). Additionally, ASYN could be detected in neurons
(Figure S5D), whereas it was absent in astrocytes (Fig-Figure 3. ASYN in iPSC-Derived O4+ Oligodendrocytes
(A) Experimental approach used for generating and assessing ASYN ex
Healthy individual, MSA-C, MSA-P, and PD patient’s skin fibroblasts
factors hKLF4, hC-MYC, hOCT4, and hSOX2. Following characterization
cytes over a period of 110 DIV.
(B) Western blotting confirms the expression of the oligodendroglial
into oligodendrocytes. Blot is representative of two independent expe
in iPSCs during oligodendrocyte differentiation.
(C) Perinuclear localization of ASYN in immature O4+ oligodendrocyte
three independent differentiations. Scale bars represent 50 mm.
(D) Presence of ASYN in O4+, CNPASE+, and MBP+ oligodendrocytes ag
ASYN and O4+/MBP+/ASYN+ oligodendrocytes are shown. Scale bars
(E) Quantification of O4+ oligodendrocytes by flow cytometry for eigh
oligodendrocytes from line 4 was observed in separate rounds of diff
(F) Quantification of O4+ oligodendrocytes co-expressing ASYN over t
(G) Quantitative real-time PCR shows SNCA transcripts in 3S iPSC-der
Stem Cure S5E). Interestingly, from 65 DIV onward, O4+ oligo-
dendrocytes displayed a perinuclear localization of ASYN
(Figures 3D and 3E), as we observed for mouse O4+ oligo-
dendrocytes (Figures 1 and 2). In cultures aged 110 DIV,
ASYN expression could still be detected in a few CNPASE+
and MBP+ mature oligodendrocytes (Figure 3D), some-
times as a perinuclear dot (Figure S6C; data not shown).
Interestingly, the disease lines CSC-4A, CSC-4B, and
CSC-3G gave rise to an accelerated high-yield generation
of O4+ oligodendrocytes (up to 70% of live single cells)
in 70 DIV (Figure 3E). Finally, we confirmed the decrease
in ASYN in O4+ oligodendrocytes over time (Figure 3F)
and the presence of SNCA transcripts in FACS-purified
O4+ oligodendrocytes from the line CSC-3S aged 80 DIV
(Figure 3G).
ASYN Protein and Transcripts Identified in
Oligodendrocytes from Mouse and Human Brains
We identified Snca transcripts in PDGFRA/CD140a+ oligo-
dendrocyte progenitors freshly isolated by FACS from
embryonic day (E)18mouse brains (Figures 4A–4C). Impor-
tantly, we detected ASYN by ICC in nearly all oligodendro-
cytes present in homogenous cultures resulting from the
isolation of E17.5 and E18 PDGFRA/CD140a+ oligodendro-
cyte progenitors (Figure 4D), ruling out the unlikely possi-
bility that ASYN may have been transferred from neurons
to oligodendrocytes in primary cultures (Figure 1). When
these progenitors matured into O4+ oligodendrocytes
(Sim et al., 2011), ASYN was still present, with the excep-
tion of a few oligodendrocytes having a more complex
morphology (Figure 4D).
Finally, we took advantage of a previously developed
technique (Ernst et al., 2014; Yeung et al., 2014), to isolate
human oligodendrocyte lineage nuclei by FACS, to assess
the presence of SNCA transcripts (Figures 4E–4I). We
prepared nuclei samples from the pons of snap-frozen
postmortem tissue from the following six patients: threepression during human iPSC-derived oligodendrocyte development.
were reprogrammed by means of viral overexpression of stemness
, human iPSCs were subsequently differentiated into oligodendro-
marker SOX10 and ASYN during the differentiation of human iPSCs
riments. Quantitative real-time PCR shows the upregulation of SNCA
s aged 65 DIV revealed by ICC. Images are representative of two to
ed 110 DIV revealed by ICC. (Middle, bottom left inset) O4+/MBP/
represent 50 mm.
t PSC lines differentiated side by side. The early emergence of O4+
erentiation.
ime is shown.
ived O4+ oligodendrocyte samples, purified by FACS.
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healthy and three diagnosed with MSA with confirmed
GCIs in oligodendrocytes (Figure S7A). We isolated from
each sample the oligodendrocyte lineage SOX10+ nuclei
and quantified neuronal NEUN+ nuclei by FACS (Fig-
ure 4G; Figure S7B). We detected a lower proportion of
neurons in the pons region of the MSA patients (Fig-
ure 4H), confirming the MSA diagnosis; we also found a
lower percentage of SOX10+ nuclei in the diseased sam-
ples, although not significant (Figure 4H). Importantly,
we could detect the presence of SNCA transcripts in
oligodendrocyte lineage nuclei of two samples isolated
from the brain of a healthy and an MSA patient (Figures
4H and 4I), as described by Asi and coworkers (Asi et al.,
2014).DISCUSSION
The absence of SNCA transcripts in oligodendrocytes in
the adult brain of healthy and MSA patients has been re-
ported repeatedly (Iwai et al., 1995; Miller et al., 2005;
Solano et al., 2000), but recent studies have challenged
these results. Because MSA has been identified as a non-
genetic disorder, it is difficult to propose an explanation
for the origin of ASYN in GCIs present in oligodendro-
cytes under pathological condition. This has led to the
emergence of a hypothesis advocating a mechanism of
cell-to-cell transfer of exogenous ASYN to oligodendro-
cytes, similar to that experimentally established from
neuron-to-neuron in PD models (Hansen et al., 2011).
However, the recent use of more advanced techniques,
such as laser-capture micro-dissection, has allowed for
the isolation of adult white matter glia from human post-
mortem tissue, resulting in the detection of SNCA tran-Figure 4. ASYN in Oligodendrocytes In Vivo
(A) Schematic representation shows the experimental approach used
(B) Quantification of PDGFRA/CD140a+ oligodendrocyte progenitors
postnatal stages, measured by FACS, is shown.
(C) Loading of quantitative real-time PCR product confirms the pres
progenitors, freshly isolated by FACS, from the mouse embryonic brai
(D) Detection of ASYN in homogenous cultures from mouse embryonic
E17.5. ASYN is maintained in homogenous cultures of PDGFRA/CD140a
The scale bar represents 50 mm.
(E) Schematic representation shows the experimental approach used
isolated from the brain of healthy and MSA patients.
(F) FACS plots represent the gating strategy employed for isolating S
(G) The decrease in the percentage of NEUN+ nuclei of the total po
compared to control (n = 3), was measured by FACS. Mean ± SEM; t t
(H) Quantitative real-time PCR shows SNCA transcripts in SOX10+ olig
T172 and T4640.
(I) Loading of quantitative real-time PCR product confirms the presenc
expression by quantitative real-time PCR recognizes a unique produc
(J) A summary of our findings is shown.
Stem Cscripts from MSA, idiopathic PD, and control cases (Asi
et al., 2014).
We clearly identified ASYN protein by ICC and western
blotting and we detected transcripts by quantitative real-
time PCR in oligodendrocyte lineage cells from rodent and
human origins (summarized in Figure 4J). We could not
detect ASYN expression in astrocytes and microglia, which
are cell types known to take up exogenous ASYN (Boza-
Serrano et al., 2014; Lee et al., 2010).Moreover, the few neu-
rons present in cultures combined with the multitude of
media changes applied during the culture period, and the
discovery of Snca/SNCA transcripts in freshly isolated oligo-
dendrocytes and ASYN protein in homogenous cultures of
freshly isolated, maturing PDGFRA/CD140a+ oligodendro-
cyte progenitors, together allow us to rule out the possibility
that healthy or dying neurons, even contaminating neu-
rons, may have released large quantities of ASYN, which
would accumulate, not being sufficiently degraded, in the
oligodendrocytes only. Moreover, we showed relocation of
ASYN during oligodendrocyte differentiation from the pro-
cesses to the perinuclear space, where the protein appears
as a single dot-like structure suggesting it is finally degraded.
We identified SNCA transcripts in human SOX10+ oligo-
dendrocyte lineage nuclei samples isolated from healthy
and MSA patients (Figure 4). This result is in line with
recent observations (Asi et al., 2014). Whether ASYN
expression identified in these two studies is reminiscent
of a basal expression in quiescent OPCs, and the difference
although not significant identified in oligodendrocytes
fromMSA and control samples is the result of a greater oli-
godendrogenesis probably triggered by neuronal injury
(Ahmed et al., 2013) remain to be determined.
We found a decrease of ASYN associated with oligo-
dendrocyte maturation characterized by complex cellularfor assessing ASYN in the mouse embryonic brain.
and O4+ oligodendrocytes from the rodent brain at embryonic and
ence of Snca transcripts in E18 PDGFRA/CD140a+ oligodendrocyte
n.
PDGFRA/CD140a+ oligodendrocyte progenitors isolated by FACS at
+ oligodendrocyte progenitors maturing into O4+ oligodendrocytes.
for assessing ASYN expression in oligodendrocyte lineage nuclei
OX10+ oligodendrocyte lineage nuclei from the samples.
pulation of all nuclei, in the pons region of MSA patients (n = 3)
est, *p < 0.05.
odendrocyte lineage nuclei samples purified by FACS from patients
e of SNCA transcripts. The set of primers used to assess human SNCA
t of 163 bp (from Asi et al., 2014).
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processes and expression of the mature marker MBP. Inter-
estingly, overexpression of ASYN in OPCs delays their
maturation into MBP+ oligodendrocytes (Ettle et al.,
2014). Additionally, we found that ASYN is decreased in
pre-myelinating oligodendrocytes, regardless of the ge-
netic background of the iPSC (diseased or healthy). This
observation, although made in vitro, may allow us to
rule out that the origin of ASYN in GCIs in MSA, and
glial inclusions in PD, may result from the accumula-
tion of a lifetime production of ASYN throughout glial
lineages.
Successful generation of patient-specific iPSCs, and
their subsequent differentiation into brain cell types,
has opened up unlimited access of patient brain cells
to a growing number of investigators interested in
studying neurodegenerative diseases. Here we have pio-
neered the generation of oligodendrocytes from MSA
and familial PD iPSC lines. Our protocol for generating
oligodendrocytes from human iPSCs, therefore, adds on
to those recently developed for studying demyelination
diseases (Douvaras et al., 2014; Numasawa-Kuroiwa
et al., 2014; Piao et al., 2015; Stacpoole et al., 2013;
Wang et al., 2013). Importantly, our iPSC models pro-
vide a greater number of lines available for studying
synucleinopathies.EXPERIMENTAL PROCEDURES
Use of Animals and Human Samples
All procedures were conducted in accordance with national and
European Union directives. The derivation of mESC and genera-
tion of human iPSC lines using viral-mediated gene delivery
were approved by the ethical committee for the use of laboratory
animals at Lund University and the Swedish Work Environment
Authority.
Primary Cell Cultures
Primary forebrain cultures were prepared from 1- to 3-day-old
wild-type mice and cultured in DMEM (Life Technologies) supple-
mented with fetal bovine serum (FBS, 10% v/v) and P/S (1% v/v).
After 3 weeks, cells were detached using trypsin, either for FACS
analysis or to be seeded on 96-well plates.
Oligodendrocyte Differentiation from Mouse and
Human PSCs
The mESC-derived oligodendrocytes were generated using a
published protocol (Czepiel et al., 2011). Human PSC (hPSC)-
derived oligodendrocytes were generated using a protocol
modified from a previously published study (Stacpoole et al.,
2013).
FACS
A FACSAria-III was used for cell sorting and analysis (MultiPark
core facility).182 Stem Cell Reports j Vol. 5 j 174–184 j August 11, 2015 j ª2015 The AutImmunostainings and Image Acquisition
ICC was carried out using standard protocols. Images were ac-
quired using an inverted epifluorescent microscope LRI-Olympus
IX-73 and a confocal microscope Leica SP8 (MultiPark core
facility).
Statistical Analyses
All quantitative data were analyzed using Prism 6.0 (GraphPad).
Sample groups were subjected to un-paired t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, seven figures, and two tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2015.07.002.
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